SCHEMBL15034110

SCHEMBL15034110

CC1(C)CN(C(=O)c2cccc(-c3ccncc3)n2)CCN1C(=O)c1ncn(-c2cccc(Cl)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
MGLL Q99685 4/20 0.38
FLT3 P36888 1/20 0.37
GSK3B P49841 1/20 0.37
IRAK4 Q9NWZ3 2/20 0.36
CFTR P13569 1/20 0.36
GRM5 P41594 2/20 0.35
MAPK1 P28482 1/20 0.34
CNR2 P34972 1/20 0.34
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
CCKAR P32238 1/20 0.33
TACR3 P29371 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034129 0.92 CFTR (0.39) ALDH1A1KDM4EMGLLIRAK4CFTR
SCHEMBL15034113 0.87 IRAK4 (0.39) SLC6A7ALDH1A1MGLLIRAK4CFTR
SCHEMBL15039441 0.87 IRAK1 (0.37) SLC6A7MGLLIRAK4CFTRGRM5
SCHEMBL15034076 0.87 SLC6A7 (0.39) SLC6A7MGLLCFTRGRM5POLB
SCHEMBL15034062 0.87 GRM5 (0.47) SLC6A7LMNAMGLLGRM5MAPK1
SCHEMBL15019498 0.86 GRM5 (0.39) SLC6A7MGLLIRAK4CFTRGRM5
SCHEMBL15034114 0.86 CLK2 (0.38) SLC6A7MGLLIRAK4POLBMAPT
SCHEMBL15034051 0.85 SLC6A7 (0.48) SLC6A7ALDH1A1KDM4ELMNAMGLL
SCHEMBL15034038 0.85 MGLL (0.40) SLC6A7MGLLIRAK4CFTRGRM5
SCHEMBL15020086 0.85 MGLL (0.36) SLC6A7MGLLCFTRGRM5CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 SLC6A7 1222/4885ALDH1A1 3952/4885KDM4E 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.